Under the terms of the agreement, Artes Medical will receive exclusive distribution and marketing rights for Elevess in the US.
Elevess is an injectable filler that reduces the appearance of facial wrinkles and folds such as nasolabial folds, and is said to be the first hyaluronic acid-based dermal filler approved by the FDA to incorporate the anesthetic lidocaine to improve patient comfort.
Charles Sherwood, Anika’s president and CEO, said: “Artes’s highly experienced sales force has well established relationships with the leading aesthetic physicians in markets throughout the US. In addition, their complementary product, deep understanding of the injectable dermal filler marketplace and compatible culture make this a highly synergistic agreement for both companies.”